Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

ABSTRACT:

Importance

A proportion of people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) have a relapsing disease course and persistent anti-myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) seropositivity. Few studies have investigated whether treatment of the first MOGAD attack is associated with the long-term disease course and/or MOG-IgG seronegative conversion.

Objective

To investigate the association of time to treat the first acute MOGAD attack with relapse risk and MOG-IgG serostatus.

Design, setting, and participants

This was a retrospective, nationwide, multicenter cohort study involving 14 secondary or tertiary hospitals in South Korea between November 2009 and August 2023. People with adult-onset MOGAD, who either had a r

SUBMITTER: Kwon YN 

PROVIDER: S-EPMC11372657 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature